Abstract
The Measurement and Treatment Research to Improve Cognition in Schizophrenia Research process has led to several developments in the assessment of cognitive functioning for schizophrenia-treatment studies. The first development was the development of a consensus cognitive battery and a United States Food and Drug Administrationendorsed research design. Since the development of the cognitive battery, interest has been spurred in clinical trials in different countries and the development of co-primary functional outcomes measures for these. The MATRICS Consensus Cognitive Battery has been translated into 11 different languages and is being translated into even more. A study has been completed that compared the usefulness of multiple potential coprimary measures, suggesting that the University of California San Diego Performance-Based skills assessment, version II (UPSA-II) is the most suitable for studies conducted in English. These findings suggest that reliable performancebased measures that are easy to administer and highly correlated with cognitive functioning are now available for use in treatment studies.
| Original language | English |
|---|---|
| Pages (from-to) | 49-52 |
| Number of pages | 4 |
| Journal | Psychiatry (Edgemont) |
| Volume | 7 |
| Issue number | 6 |
| State | Published - Jun 1 2010 |
| Externally published | Yes |
Fingerprint
Keywords
- Cognition
- Cognitive enhancement
- Disability
- Schizophrenia
ASJC Scopus subject areas
- Psychiatry and Mental health
Cite this
Latest developments in the MATRICS process. / Harvey, Philip D; Green, Michael Foster; Nuechterlein, Keith H.
In: Psychiatry (Edgemont), Vol. 7, No. 6, 01.06.2010, p. 49-52.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Latest developments in the MATRICS process
AU - Harvey, Philip D
AU - Green, Michael Foster
AU - Nuechterlein, Keith H.
PY - 2010/6/1
Y1 - 2010/6/1
N2 - The Measurement and Treatment Research to Improve Cognition in Schizophrenia Research process has led to several developments in the assessment of cognitive functioning for schizophrenia-treatment studies. The first development was the development of a consensus cognitive battery and a United States Food and Drug Administrationendorsed research design. Since the development of the cognitive battery, interest has been spurred in clinical trials in different countries and the development of co-primary functional outcomes measures for these. The MATRICS Consensus Cognitive Battery has been translated into 11 different languages and is being translated into even more. A study has been completed that compared the usefulness of multiple potential coprimary measures, suggesting that the University of California San Diego Performance-Based skills assessment, version II (UPSA-II) is the most suitable for studies conducted in English. These findings suggest that reliable performancebased measures that are easy to administer and highly correlated with cognitive functioning are now available for use in treatment studies.
AB - The Measurement and Treatment Research to Improve Cognition in Schizophrenia Research process has led to several developments in the assessment of cognitive functioning for schizophrenia-treatment studies. The first development was the development of a consensus cognitive battery and a United States Food and Drug Administrationendorsed research design. Since the development of the cognitive battery, interest has been spurred in clinical trials in different countries and the development of co-primary functional outcomes measures for these. The MATRICS Consensus Cognitive Battery has been translated into 11 different languages and is being translated into even more. A study has been completed that compared the usefulness of multiple potential coprimary measures, suggesting that the University of California San Diego Performance-Based skills assessment, version II (UPSA-II) is the most suitable for studies conducted in English. These findings suggest that reliable performancebased measures that are easy to administer and highly correlated with cognitive functioning are now available for use in treatment studies.
KW - Cognition
KW - Cognitive enhancement
KW - Disability
KW - Schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=77956087698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956087698&partnerID=8YFLogxK
M3 - Article
C2 - 20622946
AN - SCOPUS:77956087698
VL - 7
SP - 49
EP - 52
JO - Psychiatry
JF - Psychiatry
SN - 2158-8333
IS - 6
ER -